S095033 + paclitaxel

S095033 + paclitaxel is an investigational combination therapy for cancer. S095033 (also referred to as S95033) is a novel small molecule drug candidate developed by Servier, designed to target cancers with specific genetic vulnerabilities, such as MTAP-deleted tumors, through synthetic lethality. Paclitaxel is a well-established chemotherapeutic agent classified as a taxane; it works by stabilizing microtubules and inhibiting their depolymerization, thereby blocking cell division and inducing apoptosis in rapidly dividing cancer cells. The combination has been studied in early-phase clinical trials for advanced or metastatic esophageal squamous cell carcinoma (ESCC) and other solid tumors[4][7]. Paclitaxel itself is approved for the treatment of various cancers including breast, ovarian, non-small cell lung cancer, and Kaposi sarcoma[1][3][6].

Brand names

Abraxane

Other names

paclitaxel